Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Ocular adnexal MALT lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Whether Chlamydia psittaci causes this lymphoma depends on where the series was collected, and the question has not been settled in twenty years. A patient in Britain cannot be told with confidence whether an antibiotic is worth trying.
The right radiotherapy dose is unresolved: the conventional 24 to 36 Gy controls the lymphoma and causes cataract and dry eye, while very low doses of about 4 Gy spare both and have not been compared head to head here.
Bilateral disease is common and is sometimes counted as stage IV and sometimes as two localised sites, which changes the treatment a patient is offered.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
Radiotherapy to the orbit is the standard treatment for disease confined to the ocular adnexa and it controls it in almost everybody. In a series of 28 patients irradiated after a trial of doxycycline, 30 to 36 Gy in 15 to 18 fractions produced a response in all of them and a complete response in 89 per cent, with four-year progression-free survival of 74 per cent and little toxicity beyond three cases of grade 2 cataract and three of grade 1 blepharitis. Very low-dose schedules of about 4 Gy in two fractions are used to spare the lens and the tear gland, with retreatment if the lymphoma returns. Where local series have shown an association with Chlamydia psittaci, a course of doxycycline is a reasonable first step, and the same series shows that trying it first did not cost patients their response to radiotherapy afterwards.
In 28 patients whose lymphoma relapsed or progressed after doxycycline, salvage radiotherapy produced a response in every one and a complete response in 89 per cent, with four-year progression-free survival of 74 per cent.
A biopsy of the lesion is needed, because about a third of lymphomas at this site are not marginal zone lymphomas and the treatment differs. Imaging of the orbit, usually by magnetic resonance, maps the extent and the relationship to the optic nerve and the muscles. Staging of the rest of the body follows, because apparently localised ocular disease is sometimes part of a systemic marginal zone lymphoma. Both orbits are examined; bilateral disease is common and does not by itself mean the lymphoma has spread.
A United States study tested 28 ocular adnexal lymphoma specimens with two polymerase chain reaction assays and found no Chlamydia psittaci DNA, and noted that the association has been reported internationally with great variability.
Italian investigators reported the bacterium of psittacosis in ocular adnexal marginal zone lymphomas and showed that doxycycline produced regression in a proportion of patients.